2025
#fff
FDA accepts Alnylam’s siRELISTM enzymatic ligation manufacturing platform into its Emerging Technology Program, fast-tracking global regulatory engagement
4
https://investors.alnylam.com/press-release?id=29466
On
You will be redirected to an external site that may include social media, event registration, or other third-party content related to Alnylam.
Please note that these external sites have their own terms of service and privacy policies, which may differ from those of Alnylam.
Proceed to Site